Cochlear Limited's (ASX:COH) price-to-earnings (or "P/E") ratio of 65.3x might make it look like a strong sell right now compared to the market in Australia, where around half of the companies have ...

Cochlear (ASX:COH) has had a great run on the share market with its stock up by a significant 9.3% over the last week. Given that stock prices are usually aligned with a company's financial ...

LONE TREE, Colo., March 3, 2025 /PRNewswire/ — In celebration of World Hearing Day, Cochlear, the global leader in implantable hearing solutions, is proud to announce that it has been named the number ...

Cochlear Limited (AU:COH) has released an update. Cochlear Limited recently reported changes in the interests of its director, Diggory William Howitt, involving the acquisition of 11,000 shares and ...

CENTENNIAL, Colo., June 17, 2019 /PRNewswire/ -- Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, today announced the U.S. Food and Drug Administration's (FDA) approval ...

Cochlear Limited, a medical device company specializing in implantable hearing solutions, is launching two new bone conduction sound processor devices for patients with high levels of hearing loss.

Thanks, everyone, for joining on short notice this morning. As I said, we're going to make a few comments to open. What I'd like to do is talk through what are the issues that are impacting the ...

Today we'll look at Cochlear Limited (ASX:COH) and reflect on its potential as an investment. In particular, we'll consider its Return On Capital Employed (ROCE), as that can give us insight into how ...

The big shareholder groups in Cochlear Limited (ASX:COH) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit ...

Thank you for standing by, and welcome to the Cochlear Limited HY '26 Results Analyst and Media Briefing. [Operator Instructions] I would now like to turn the conference over to Mr. Dig Howitt, CEO ...

MONTPELLIER, France & SYDNEY--(BUSINESS WIRE)--Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology, which specializes in the development of novel ...